Euglycemic diabetic ketoacidosis in type 2 diabetes mellitus patients following SGLT2i use: a case report
Abstract
Background: While relatively rare in type 2 diabetes mellitus (T2DM), diabetic ketoacidosis (DKA) is a serious complication that occurs due to absolute or relative insulin deficiency. Euglycemic DKA (EDKA) is a variant of DKA where patients present with normal blood sugar levels. Recently, studies have reported increased incidence of EDKA associated with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, medications used to manage blood glucose.Case Presentation: A 53-year-old man with newly diagnosed T2DM presented with severe nausea and vomiting 4 days after the initiation of empagliflozin/metformin. Laboratory evaluation revealed metabolic acidosis (pH 7.16, bicarbonate 12 mmol/l), elevated anion gap (21 mmol/l), and increased serum ketones, despite near-normal blood glucose levels (7.8 mmol/l, approximately 140 mg/dl). A diagnosis of EDKA was made. The patient was treated with intravenous fluids, insulin therapy, and electrolyte replacement, with discontinuation of the SGLT2 inhibitor. He showed rapid clinical and biochemical improvement and was discharged on insulin therapy, later transitioning to oral agents.Conclusion: EDKA should be suspected in patients receiving SGLT2 inhibitors who present with unexplained metabolic acidosis, even in the absence of significant hyperglycemia. Early recognition and prompt management are essential to prevent complications.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.